Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
48
AZN Quote, Financials, Valuation and Earnings
Last price:
$66.30
Seasonality move
:
1.27%
Day range:
$65.93 - $66.50
52-week range:
$60.47 - $87.68
Dividend yield:
2.24%
P/E ratio:
31.80x
P/S ratio:
4.05x
P/B ratio:
5.05x
Volume:
2.2M
Avg. volume:
6.3M
1-year change:
0.02%
Market cap:
$205.6B
Revenue:
$45.8B
EPS (TTM):
$2.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.1B | $1.03 | 17.56% | 255.34% | -- |
|
AMGN
Amgen
|
$8.5B | $5.11 | 8.07% | 255.18% | $322.43 |
|
GSK
GSK PLC
|
$10.4B | $1.16 | -1.61% | 107.8% | $42.93 |
|
JNJ
Johnson & Johnson
|
$22.2B | $2.21 | 4.95% | 21.99% | $172.53 |
|
MRNA
Moderna
|
$1.2B | -$1.94 | -63.53% | -79.68% | $127.09 |
|
SNY
Sanofi SA
|
$13.7B | $1.38 | -9.77% | 26.36% | $63.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$66.30 | -- | $205.6B | 31.80x | $0.50 | 2.24% | 4.05x |
|
AMGN
Amgen
|
$264.49 | $322.43 | $142.2B | 33.87x | $2.25 | 3.4% | 4.38x |
|
GSK
GSK PLC
|
$34.03 | $42.93 | $69.4B | 22.12x | $0.39 | 4.6% | 1.77x |
|
JNJ
Johnson & Johnson
|
$145.85 | $172.53 | $351.2B | 24.11x | $1.24 | 3.33% | 4.04x |
|
MRNA
Moderna
|
$40.27 | $127.09 | $15.5B | -- | $0.00 | 0% | 3.08x |
|
SNY
Sanofi SA
|
$48.29 | $63.06 | $121.1B | 24.47x | $2.04 | 8.15% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.54% | -0.572 | 12.47% | 0.71x |
|
AMGN
Amgen
|
88.92% | -0.086 | 34.87% | 0.80x |
|
GSK
GSK PLC
|
53.41% | 0.747 | 26% | 0.52x |
|
JNJ
Johnson & Johnson
|
33.76% | 0.599 | 9.16% | 0.70x |
|
MRNA
Moderna
|
-- | 0.826 | -- | 3.95x |
|
SNY
Sanofi SA
|
23.02% | -0.094 | -- | 0.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$10.5B | $2.1B | 9.41% | 16.72% | 16.85% | $2B |
|
AMGN
Amgen
|
$5.2B | $2B | 6.14% | 65.35% | 45.6% | $3.3B |
|
GSK
GSK PLC
|
$7.3B | $245.9M | 8.08% | 18.89% | 2.75% | $1.7B |
|
JNJ
Johnson & Johnson
|
$15.5B | $5.3B | 14.07% | 20.88% | 15.71% | $5.7B |
|
MRNA
Moderna
|
$1.3B | -$70M | -17.44% | -17.44% | 1.46% | -$1.7B |
|
SNY
Sanofi SA
|
$11.1B | $4.5B | 4.56% | 5.8% | 26.62% | -$498.5M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 33.28%. AstraZeneca PLC's return on equity of 16.72% beat Amgen's return on equity of 65.35%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B AMGNAmgen61.07% $5.22 $67.9B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.75%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 21.91%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 AMGNAmgen10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Amgen offers a yield of 3.4% to investors and pays a quarterly dividend of $2.25 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.5B. AstraZeneca PLC's net income of $1.4B is lower than Amgen's net income of $2.8B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.80x while Amgen's PE ratio is 33.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.05x versus 4.38x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.05x 31.80x $13.6B $1.4B AMGNAmgen4.38x 33.87x $8.5B $2.8B
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of -0.72%. AstraZeneca PLC's return on equity of 16.72% beat GSK PLC's return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B GSKGSK PLC70.08% -$0.04 $39.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.75%. On the other hand GSK PLC has an analysts' consensus of $42.93 which suggests that it could grow by 32.46%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 GSKGSK PLC2 4 0 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.349%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. GSK PLC offers a yield of 4.6% to investors and pays a quarterly dividend of $0.39 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. GSK PLC pays out 45.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.4B is higher than GSK PLC's net income of -$75.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.80x while GSK PLC's PE ratio is 22.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.05x versus 1.77x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.05x 31.80x $13.6B $1.4B GSKGSK PLC1.77x 22.12x $10.4B -$75.5M
-
Which has Higher Returns AZN or JNJ?
Johnson & Johnson has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 11.99%. AstraZeneca PLC's return on equity of 16.72% beat Johnson & Johnson's return on equity of 20.88%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B JNJJohnson & Johnson69.01% $1.11 $105.9B -
What do Analysts Say About AZN or JNJ?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.75%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.49%. Given that AstraZeneca PLC has higher upside potential than Johnson & Johnson, analysts believe AstraZeneca PLC is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 JNJJohnson & Johnson8 13 0 -
Is AZN or JNJ More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.
-
Which is a Better Dividend Stock AZN or JNJ?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Johnson & Johnson offers a yield of 3.33% to investors and pays a quarterly dividend of $1.24 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or JNJ?
AstraZeneca PLC quarterly revenues are $13.6B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AstraZeneca PLC's net income of $1.4B is lower than Johnson & Johnson's net income of $2.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.80x while Johnson & Johnson's PE ratio is 24.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.05x versus 4.04x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.05x 31.80x $13.6B $1.4B JNJJohnson & Johnson4.04x 24.11x $22.5B $2.7B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 0.7%. AstraZeneca PLC's return on equity of 16.72% beat Moderna's return on equity of -17.44%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B MRNAModerna72.29% $0.03 $11.9B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.75%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 MRNAModerna7 12 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $1.9B. AstraZeneca PLC's net income of $1.4B is higher than Moderna's net income of $13M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.80x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.05x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.05x 31.80x $13.6B $1.4B MRNAModerna3.08x -- $1.9B $13M
-
Which has Higher Returns AZN or SNY?
Sanofi SA has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 19.88%. AstraZeneca PLC's return on equity of 16.72% beat Sanofi SA's return on equity of 5.8%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B SNYSanofi SA71.15% $1.24 $101.5B -
What do Analysts Say About AZN or SNY?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.75%. On the other hand Sanofi SA has an analysts' consensus of $63.06 which suggests that it could grow by 30.59%. Given that AstraZeneca PLC has higher upside potential than Sanofi SA, analysts believe AstraZeneca PLC is more attractive than Sanofi SA.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 SNYSanofi SA5 1 0 -
Is AZN or SNY More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.492%.
-
Which is a Better Dividend Stock AZN or SNY?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Sanofi SA offers a yield of 8.15% to investors and pays a quarterly dividend of $2.04 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Sanofi SA pays out 82.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SNY?
AstraZeneca PLC quarterly revenues are $13.6B, which are smaller than Sanofi SA quarterly revenues of $15.6B. AstraZeneca PLC's net income of $1.4B is lower than Sanofi SA's net income of $3.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.80x while Sanofi SA's PE ratio is 24.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.05x versus 2.28x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.05x 31.80x $13.6B $1.4B SNYSanofi SA2.28x 24.47x $15.6B $3.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
